Loading...
ERBB2
Loading...Anti-ERBB2 Products
- Anti-ERBB2 immunotoxin 4D5 (scFv)-DT (AGTO-G022D)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
-
- Derivation: Chimeric (Human/Mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: IF, IP, Neut, FuncS, ELISA, FC, WB
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: FuncS, IF, Neut, ELISA, FC, IP, WB
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA, WB, FuncS
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA, WB, FuncS
- Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-0191CL-S(P)) (TAB-0191CL-S(P))
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, Cyt, Internalization
-
- Species Reactivity: Human
- Type: Human IgG
- Application: WB, IF, FuncS
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, WB, FuncS
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IFNα
- Host: Chimeric (Human-Mouse)
- Cytokine 1 Species: Mouse
- Molecule Class: L Kappa; IgG1-IFNα
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, WB, FuncS
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: RLI-scFv
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: RLI-IgG1
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL2
- Host: Humanized from Mouse
- Cytokine 1 Species: Human
- Molecule Class: scFv‑Fc‑IL2
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Cytokine 2: L22
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: IL15-L22-scFv
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Cytokine 2: L22
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: L kappa; IL15-L22-IgG1
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Host: Mouse
- Cytokine 1 Species: Human
- Molecule Class: IgG-IL15
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Cytokine 2: L22
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: RLI-L22-scFv
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Host: Mouse
- Cytokine 1 Species: Human
- Molecule Class: scFv-IL15
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Cytokine 2: L22
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: L kappa; RLI-L22-IgG1
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: GM-CSF
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: IgG3-GM-CSF
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL12
- Cytokine 2: IL2
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: L kappa; IL12-IgG1-IL2
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IFNα
- Host: Human
- Cytokine 1 Species: Mouse
- Molecule Class: IgG3-IFNα
-
- Derivation: Human
- Species Reactivity: Human
- Type: Llama VHH
- Application: SPR
-
- Derivation: Human
- Species Reactivity: Human
- Type: Llama VHH
- Application: SPR
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Llama VHH
- Application: ELISA
-
- Species Reactivity: Human
- Type: Human scFv
- Application: WB
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL12
- Cytokine 2: GM-CSF
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: L kappa; IL12-IgG1-GM-CSF
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IFNα
- Host: Chimeric (Human-Mouse)
- Cytokine 1 Species: Human
- Molecule Class: L Kappa; IgG1-IFNα
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA, WB, FuncS
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA, WB, FuncS
- Anti-ERBB2 immunotoxin 4D5 (scFv)-PE (AGTO-G022E)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
-
- Species Reactivity: Human
- Type: Llama VHH
- Application: IHC, FC, CA, FuncS
- Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel (AGTO-G022G)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA (AGTO-G022R)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap (AGTO-G022S)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Anti-Her-2 receptor-Phor18 molecules ADC (ADC-132CL)
-
- Target: Her-2 receptor
- Linker: 2, 4 or 6 Phor18 molecules
- Anti-HER2-Gly5-modified DM1 ADC (ADC-147CL)
-
- Target: HER2
- Drug: Gly5-modified DM1 (Gly5-modified N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-vcPAB-MMAE ADC (ADC-148CL)
-
- Target: HER2
- Linker: VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: MMAE (Monomethyl auristatin E)
- Anti-Her2-ALKYNE-MMAF ADC (ADC-209CL)
-
- Target: Her2
- Linker: ALKYNE
- Drug: MMAF (Monomethyl auristatin F)
- Anti-Her2-VCP-cyclooctyne-MMAF ADC (ADC-210CL)
-
- Target: Her2
- Linker: valine-citruline-p-amino-benzoyl-carbonate (VCP)-cyclooctyne
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (clone hu4D5Fabv8)-MC-vc-PAB-MMAF ADC (ADC-183CL)
-
- Target: HER2
- Linker: MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: MMAF (Monomethyl auristatin F)
-
- Target: HER2
- Linker: hydroxyl amino PEG linker
- Drug: MMAD (monomethyl auristatin D)
-
- Target: HER2
- Linker: thioether SMCC linker
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-NGMs-MMAE ADC (ADC-035LZY)
-
- Target: HER2
- Linker: NGMs(next generation maleimides)
- Drug: MMAE (monomethyl auristatin E)
-
- Target: HER2
- Linker: MC-PEG8
- Drug: Dol10 (Thiol Dol10)
-
- Target: HER2
- Linker: AO-Mc-PEG8
- Drug: Dol10 (Thiol Dol10)
- Anti-HER2-DBM-MMAF ADC (ADC-105LZY)
-
- Target: HER2
- Linker: DBM(dibromomaleimide)
- Drug: MMAF(monomethyl auristatin F)
- Anti-HER2 (Trastuzumab)-MC-MMAE (Thiol MMAE) ADC (ADC-103LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2-mc-MMAF ADC (ADC-107LZY)
-
- Target: HER2
- Linker: mc(maleimidocaproyl)
- Drug: MMAF(monomethyl auristatin F)
- Anti-HER2 (Trastuzumab)-AO-MC-MMAE (Glyco MMAE) ADC (ADC-104LCT)
-
- Target: HER2
- Linker: AO-Mc-
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2-Amberstatin (AS269) ADC (ADC-109LZY)
-
- Target: HER2
- Linker: non-natural amino acids (Ambrx' technology)
- Drug: Amberstatin (AS269)
- Anti-HER2-vandetanib ADC (ADC-068LZY)
-
- Target: HER2
- Drug: vandetanib
- Anti-HER2-DUBA-Duocarmycins ADC (ADC-069LZY)
-
- Target: HER2
- Linker: DUBA (DUocarmycinhydroxyBenzamide-Azaindole
linker) ("mc"-VC-PABC-CM) - Drug: Duocarmycins
- Anti-HER2 (trastuzumab) Fab-bisAlk-vc-MMAE ADC (ADC-122LCT)
-
- Target: HER2
- Linker: bisAlk-VC
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2-DOX ADC (ADC-131LZY)
-
- Target: HER2
- Linker: thiomaleamicacids-p-aminobenzyloxycarbonyl
- Drug: doxorubicin
- Anti-HER2-vc-MMAE ADC (ADC-081LZY)
-
- Target: HER2
- Linker: VC (valine-citrulline)
- Drug: MMAE(monomethyl auristatin E)
- Anti-HER2-SPP-DM1 ADC (ADC-132LZY)
-
- Target: HER2
- Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-HER2-vc-Duostatin-3 ADC (ADC-087LZY)
-
- Target: HER2
- Linker: VC (valine-citrulline)
- Drug: Duostatin-3
- Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] (IAB-B008(A))
-
- Species Reactivity: human
- Type: scFv-(D-Arg)9
- Application: IF, FC, FuncS
- Recombinant Anti-human ERBB2 Intrabody [+36 GFP] (IAB-B008(G))
-
- Species Reactivity: human
- Type: scFv-(+36GFP)
- Application: WB, ICC, FuncS
- Recombinant Anti-human ERBB2 Intrabody [Tat] (IAB-B008(T))
-
- Species Reactivity: human
- Type: scFv-Tat
- Application: ICC, Neut, FuncS
- Anti-HER2 (trastuzumab)-bisAlk-vc-MMAE ADC (ADC-123LCT)
-
- Target: HER2
- Linker: bisAlk-VC
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2 (Trastuzumab)-CC-MMAD ADC (ADC-126LCT)
-
- Target: HER2
- Linker: CC
- Drug: MMAD (monomethyl auristatin D)
- Anti-HER2 (Trastuzumab)-mc-MMAD ADC (ADC-127LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAD (monomethyl auristatin D)
- Anti-HER2 (trastuzumab)-mc-c-term-Dol15 ADC (ADC-128LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: dolastatin 15 derivatives (Dol15)
- Anti-HER2 (trastuzumab)-mcc-DM1 ADC (ADC-129LCT)
-
- Target: HER2
- Linker: mcc (Maleimidomethyl cyclohexane-1-carboxylate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- thio-Anti-HER2 (trastuzumab)-mpeo-DM1 ADC (ADC-130LCT)
-
- Target: HER2
- Linker: mpeo
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2 (trastuzumab)-NGM-doxorubicin ADC (ADC-131LCT)
-
- Target: HER2
- Linker: NGM
- Drug: doxorubicin
- Anti-HER2-MT-vc-MMAE ADC (ADC-249CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
-
- Target: HER2
- Linker: mcc (Maleimidomethyl cyclohexane-1- carboxylate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto- 1-oxopropyl)maytansine)
- Anti-HER2 (trastuzumab)-SPDP-DM1 ADC (ADC-134LCT)
-
- Target: HER2
- Linker: SPDP ( N-succinimidyl 3-(2-pyridyldithio)propionate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2 (trastuzumab)-SPP-DM1 ADC (ADC-135LCT)
-
- Target: HER2
- Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-MT-vc-MMAE ADC (ADC-248CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-[14C]-SMCC-DM1 ADC (ADC-150LZY)
-
- Target: HER2
- Linker: [14C]-SMCC
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-Her2-saporin 6 A157C ADC (ADC-164LZY)
-
- Target: Her2
- Linker: aminooxy-maleimide linker
- Drug: saporin 6 A157C
- Anti-Her2-MCC-DM1 ADC (ADC-174LZY)
-
- Target: Her2
- Linker: MCC (Maleimidomethyl cyclohexane-1-carboxylate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-Her2-mc-vc-PABC-MMAE ADC (ADC-175LZY)
-
- Target: Her2
- Linker: mc-VC-PABC (maleimidocaproyl valine-citrulline-p-aminobenzyl carbamoyl)
- Drug: MMAE (monomethyl auristatin E)
-
- Target: HER2
- Linker: vc (valine-citrulline)
- Drug: Duocarmycins
- Anti-HER2-MODO ADC (ADC-264CL)
-
- Target: HER2
- Drug: MODO (monomethyldolastatin)
- Anti-HER2-DBCO-MMAF ADC (ADC-295CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-296CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-297CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-298CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-299CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-300CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-307CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-308CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-DBCO-MMAF ADC (ADC-309CL)
-
- Target: HER2
- Linker: DBCO (Dibenzocyclooctyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (clone hu4D5Fabv8)-MC-MMAF ADC (ADC-184CL)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (clone hu4D5Fabv8)-BMPEO-DM1 ADC (ADC-185CL)
-
- Target: HER2
- Linker: BMPEO (bis-maleimido-trioxyethylene glycol)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-BMPEO-DM1 ADC (ADC-186CL)
-
- Target: HER2
- Linker: BMPEO (bis-maleimido-trioxyethylene glycol)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-Her2-vc-[14C]MMAE ADC (ADC-221LZY)
-
- Target: Her2
- Linker: VC(valine-citrulline)
- Drug: [14C]MMAE(14C-labeled monomethyl auristatin E)
- Anti-HER2 (trastuzumab)-SSNPP-DM4 ADC (ADC-137LCT)
-
- Target: HER2
- Linker: SSNPP
- Drug: DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
- Anti-HER2-MT-vc-MMAE ADC (ADC-250CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2 (trastuzumab)-auristatin ADC (ADC-138LCT)
-
- Target: HER2
- Linker: The linker contains two ethylene glycol moieties modified with a terminal alkoxy-amine group to improve solubility and minimize export of the more hydrophilic derivatized analogs by drug pumps
- Drug: auristatin
- Anti-HER2 Fab (trastuzumab)-Porphyrin ADC (ADC-139LCT)
-
- Target: HER2
- Drug: Porphyrin
- Anti-HER2 (trastuzumab)-SSNPP-DM3 ADC (ADC-136LCT)
-
- Target: HER2
- Linker: SSNPP
- Drug: DM3
- Anti-HER2-MT-vc-MMAE ADC (ADC-251CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins
Intracellular, Membrane (different isoforms)
Cell type enhanced (Collecting duct cells, Proximal enterocytes, Distal enterocytes)
Immune cell enhanced (gdT-cell)
Group enriched (OE19, SK-BR-3)
Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:21190959, PubMed:16978839). Part of a complex with EGFR and either PIK3C2A or PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196 (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151). Interacts with MUC1; the interaction is enhanced by heregulin (HRG) (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1, RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6 (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369). Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts (preferentially with the tyrosine phosphorylated form) with CPNE3; this interaction occurs at the cell membrane and is increased in a growth factor heregulin-dependent manner (PubMed:20010870). Interacts with HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with SORL1; this interaction regulates ERBB2 subcellular distribution by promoting its recycling after internalization from endosomes back to the plasma membrane, hence stimulates ERBB2-mediated signaling (PubMed:31138794).
Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase


Bladder Cancer
Non-small Cell Lung Cancer
ErbB Signaling Pathway
